{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:05:46Z","timestamp":1794002746388,"version":"4.8.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00277-025-06216-1","type":"journal-article","created":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T22:15:57Z","timestamp":1737324957000},"page":"881-893","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A review on disease modifying pharmacologic therapies for sickle cell disease"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2083-5510","authenticated-orcid":false,"given":"Himil","family":"Mahadevia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Ponvilawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ujjwal","family":"Madan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Qasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"issue":"1","key":"6216_CR1","doi-asserted-by":"publisher","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","volume":"4","author":"GJ Kato","year":"2018","unstructured":"Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, Smith WR, Panepinto JA, Weatherall DJ, Costa FF, Vichinsky EP (2018) Sickle cell disease. Nat Reviews Disease Primers 4(1):18010. https:\/\/doi.org\/10.1038\/nrdp.2018.10","journal-title":"Nat Reviews Disease Primers"},{"issue":"4 Suppl","key":"6216_CR2","doi-asserted-by":"publisher","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","volume":"38","author":"KL Hassell","year":"2010","unstructured":"Hassell KL (2010) Population estimates of sickle cell disease in the U.S. Am J Prev Med 38(4 Suppl):S512\u2013521. https:\/\/doi.org\/10.1016\/j.amepre.2009.12.022","journal-title":"Am J Prev Med"},{"issue":"7","key":"6216_CR3","doi-asserted-by":"publisher","first-page":"e1001484","DOI":"10.1371\/journal.pmed.1001484","volume":"10","author":"FB Piel","year":"2013","unstructured":"Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN (2013) Global Burden of Sickle Cell Anaemia in Children under five, 2010\u20132050: Modelling based on demographics, excess mortality, and interventions. PLoS Med 10(7):e1001484. https:\/\/doi.org\/10.1371\/journal.pmed.1001484","journal-title":"PLoS Med"},{"issue":"2","key":"6216_CR4","first-page":"8","volume":"2","author":"B Lutz","year":"2015","unstructured":"Lutz B, Meiler SE, Bekker A, Tao YX (2015) Updated mechanisms of Sickle Cell Disease-Associated Chronic pain. Transl Perioper Pain Med 2(2):8\u201317","journal-title":"Transl Perioper Pain Med"},{"issue":"1","key":"6216_CR5","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.4081\/hr.2010.e2","volume":"2","author":"OO Ilesanmi","year":"2010","unstructured":"Ilesanmi OO (2010) Pathological basis of symptoms and crises in sickle cell disorder: implications for counseling and psychotherapy. Hematol Rep 2(1):e2. https:\/\/doi.org\/10.4081\/hr.2010.e2","journal-title":"Hematol Rep"},{"issue":"3","key":"6216_CR6","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1172\/jci89741","volume":"127","author":"GJ Kato","year":"2017","unstructured":"Kato GJ, Steinberg MH, Gladwin MT (2017) Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest 127(3):750\u2013760. https:\/\/doi.org\/10.1172\/jci89741","journal-title":"J Clin Invest"},{"issue":"11","key":"6216_CR7","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1182\/blood.V112.11.1439.1439","volume":"112","author":"T Presley","year":"2008","unstructured":"Presley T, Bain L, Ballas S, Nichols J, Sabio H, Gladwin M, Kato GJ, Kim-Shapiro D (2008) The mechanism of Hemolysis in Sickle Cell Anemia. Blood 112(11):1439\u20131439. https:\/\/doi.org\/10.1182\/blood.V112.11.1439.1439","journal-title":"Blood"},{"issue":"1","key":"6216_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1365-2141.2008.07155.x","volume":"142","author":"M Westerman","year":"2008","unstructured":"Westerman M, Pizzey A, Hirschman J, Cerino M, Weil-Weiner Y, Ramotar P, Eze A, Lawrie A, Purdy G, Mackie I, Porter J (2008) Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. Br J Haematol 142(1):126\u2013135. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07155.x","journal-title":"Br J Haematol"},{"issue":"2\u20133","key":"6216_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3233\/ch-189012","volume":"68","author":"N Conran","year":"2018","unstructured":"Conran N, Belcher JD (2018) Inflammation in sickle cell disease. Clin Hemorheol Microcirc 68(2\u20133):263\u2013299. https:\/\/doi.org\/10.3233\/ch-189012","journal-title":"Clin Hemorheol Microcirc"},{"issue":"11","key":"6216_CR10","doi-asserted-by":"publisher","first-page":"e0165833","DOI":"10.1371\/journal.pone.0165833","volume":"11","author":"LS Torres","year":"2016","unstructured":"Torres LS, Okumura JV, Silva DGH, Mimura KKO, Belini-J\u00fanior \u00c9, Oliveira RG, Lobo CLC, Oliani SM, Bonini-Domingos CR (2016) Inflammation in Sickle Cell Disease: Differential and Down-expressed plasma levels of annexin A1 protein. PLoS ONE 11(11):e0165833. https:\/\/doi.org\/10.1371\/journal.pone.0165833","journal-title":"PLoS ONE"},{"issue":"2\u20133","key":"6216_CR11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3233\/ch-189013","volume":"68","author":"C Faes","year":"2018","unstructured":"Faes C, Sparkenbaugh EM, Pawlinski R (2018) Hypercoagulable state in sickle cell disease. Clin Hemorheol Microcirc 68(2\u20133):301\u2013318. https:\/\/doi.org\/10.3233\/ch-189013","journal-title":"Clin Hemorheol Microcirc"},{"issue":"4","key":"6216_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1046\/j.1365-2141.1998.00627.x","volume":"100","author":"T Wun","year":"1998","unstructured":"Wun T, Paglieroni T, Rangaswami A, Franklin PH, Welborn J, Cheung A, Tablin F (1998) Platelet activation in patients with sickle cell disease. Br J Haematol 100(4):741\u2013749. https:\/\/doi.org\/10.1046\/j.1365-2141.1998.00627.x","journal-title":"Br J Haematol"},{"key":"6216_CR13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1182\/asheducation-2013.1.370","volume":"2013","author":"E Gluckman","year":"2013","unstructured":"Gluckman E (2013) Allogeneic transplantation strategies including haploidentical transplantation in sickle cell disease. Hematol Am Soc Hematol Educ Program 2013:370\u2013376. https:\/\/doi.org\/10.1182\/asheducation-2013.1.370","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"11","key":"6216_CR14","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.3324\/haematol.2017.169581","volume":"102","author":"DA Staci","year":"2017","unstructured":"Staci DA, Ruta B, Naya H, Yimei L, Richard A, Zhezhen J, Matt H, Yoshiko A, Jignesh D, Theresa H, Nandita K, Carmem B, Navneet SM, Miguel Angel D, Cesar OF, William AW, Bipin NS, Rammurti TK, Susan P, Ibrahim A, Keith S, Sara B, Christopher D, Reinhold M, Susana M, Menachem B, Hisham A-A, Mahmoud A, Richard FO, Sarita J, Dave B, Michael JE, Shahrukh H, Hillard L, David IM, Amir S, Ayman S, Usama G, Lakshmanan K, Allistair A, Hemalatha GR, Mark W, Joseph L, Wael S, Prakash S (2017) Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. Haematologica 102(11):1823\u20131832. https:\/\/doi.org\/10.3324\/haematol.2017.169581","journal-title":"Haematologica"},{"issue":"4","key":"6216_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/MPH.0b013e31828d5e6a","volume":"35","author":"NA Omondi","year":"2013","unstructured":"Omondi NA, Ferguson SE, Majhail NS, Denzen EM, Buchanan GR, Haight AE, Labotka RJ, Rizzo JD, Murphy EA (2013) Barriers to hematopoietic cell transplantation clinical trial participation of African American and black youth with sickle cell disease and their parents. J Pediatr Hematol Oncol 35(4):289\u2013298. https:\/\/doi.org\/10.1097\/MPH.0b013e31828d5e6a","journal-title":"J Pediatr Hematol Oncol"},{"key":"6216_CR16","doi-asserted-by":"crossref","unstructured":"Krishnamurti L (2021) Hematopoietic cell transplantation for Sickle Cell Disease. Front Pead 8","DOI":"10.3389\/fped.2020.551170"},{"issue":"20","key":"6216_CR17","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","volume":"332","author":"S Charache","year":"1995","unstructured":"Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR (1995) Effect of Hydroxyurea on the frequency of painful crises in Sickle Cell Anemia. N Engl J Med 332(20):1317\u20131322. https:\/\/doi.org\/10.1056\/NEJM199505183322001","journal-title":"N Engl J Med"},{"issue":"13","key":"6216_CR18","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1001\/jama.289.13.1645","volume":"289","author":"MH Steinberg","year":"2003","unstructured":"Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M (2003) Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 289(13):1645\u20131651. https:\/\/doi.org\/10.1001\/jama.289.13.1645","journal-title":"JAMA"},{"issue":"12","key":"6216_CR19","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/ajh.20703","volume":"81","author":"S Lanzkron","year":"2006","unstructured":"Lanzkron S, Haywood C Jr., Segal JB, Dover GJ (2006) Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. Am J Hematol 81(12):927\u2013932. https:\/\/doi.org\/10.1002\/ajh.20703","journal-title":"Am J Hematol"},{"issue":"7","key":"6216_CR20","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1001\/jama.2017.10152","volume":"318","author":"R Voelker","year":"2017","unstructured":"Voelker R (2017) Sickle Cell Therapy Drought ends. JAMA 318(7):604\u2013604. https:\/\/doi.org\/10.1001\/jama.2017.10152","journal-title":"JAMA"},{"issue":"3","key":"6216_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2029392","volume":"384","author":"EB Esrick","year":"2021","unstructured":"Esrick EB, Lehmann LE, Biffi A, Achebe M, Brendel C, Ciuculescu MF, Daley H, MacKinnon B, Morris E, Federico A, Abriss D, Boardman K, Khelladi R, Shaw K, Negre H, Negre O, Nikiforow S, Ritz J, Pai SY, London WB, Dansereau C, Heeney MM, Armant M, Manis JP, Williams DA (2021) Post-transcriptional genetic silencing of BCL11A to treat Sickle Cell Disease. N Engl J Med 384(3):205\u2013215. https:\/\/doi.org\/10.1056\/NEJMoa2029392","journal-title":"N Engl J Med"},{"key":"6216_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/5584_2018_331","volume":"1144","author":"S Demirci","year":"2019","unstructured":"Demirci S, Leonard A, Haro-Mora JJ, Uchida N, Tisdale JF (2019) CRISPR\/Cas9 for Sickle Cell Disease: applications, future possibilities, and challenges. Adv Exp Med Biol 1144:37\u201352. https:\/\/doi.org\/10.1007\/5584_2018_331","journal-title":"Adv Exp Med Biol"},{"issue":"7","key":"6216_CR23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2117175","volume":"386","author":"J Kanter","year":"2022","unstructured":"Kanter J, Walters MC, Krishnamurti L, Mapara MY, Kwiatkowski JL, Rifkin-Zenenberg S, Aygun B, Kasow KA, Pierciey FJ Jr., Bonner M, Miller A, Zhang X, Lynch J, Kim D, Ribeil JA, Asmal M, Goyal S, Thompson AA, Tisdale JF (2022) Biologic and clinical efficacy of LentiGlobin for Sickle Cell Disease. N Engl J Med 386(7):617\u2013628. https:\/\/doi.org\/10.1056\/NEJMoa2117175","journal-title":"N Engl J Med"},{"issue":"1","key":"6216_CR24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0006-291X(68)90266-0","volume":"33","author":"HL Elford","year":"1968","unstructured":"Elford HL (1968) Effect of hydroxyurea on ribonucleotide reductase. Biochem Biophys Res Commun 33(1):129\u2013135. https:\/\/doi.org\/10.1016\/0006-291X(68)90266-0","journal-title":"Biochem Biophys Res Commun"},{"key":"6216_CR25","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1749-6632.1985.tb17188.x","volume":"445","author":"G Stamatoyannopoulos","year":"1985","unstructured":"Stamatoyannopoulos G, Veith R, Galanello R, Papayannopoulou T (1985) Hb F production in stressed erythropoiesis: observations and kinetic models. Ann N Y Acad Sci 445:188\u2013197. https:\/\/doi.org\/10.1111\/j.1749-6632.1985.tb17188.x","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"6216_CR26","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/1096-8652(200011)65:3<227::AID-AJH9>3.0.CO;2-V","volume":"65","author":"BS Baliga","year":"2000","unstructured":"Baliga BS, Pace BS, Chen H-H, Shah AK, Yang Y-M (2000) Mechanism for fetal hemoglobin induction by hydroxyurea in sickle cell erythroid progenitors. Am J Hematol 65(3):227\u2013233. https:\/\/doi.org\/10.1002\/1096-8652(200011)65:3%3C227::AID-AJH9%3E3.0.CO;2-V","journal-title":"Am J Hematol"},{"issue":"11","key":"6216_CR27","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1517\/14740338.2015.1088827","volume":"14","author":"PT McGann","year":"2015","unstructured":"McGann PT, Ware RE (2015) Hydroxyurea therapy for sickle cell anemia. Exp Opin Drug Saf 14(11):1749\u20131758. https:\/\/doi.org\/10.1517\/14740338.2015.1088827","journal-title":"Exp Opin Drug Saf"},{"issue":"10","key":"6216_CR28","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1182\/blood.V79.10.2555.2555","volume":"79","author":"S Charache","year":"1992","unstructured":"Charache S, Dover GJ, Moore RD, Eckert S, Ballas SK, Koshy M, Milner PF, Orringer EP, Phillips G Jr., Platt OS et al (1992) Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood 79(10):2555\u20132565","journal-title":"Blood"},{"issue":"6","key":"6216_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ajh.21699","volume":"85","author":"MH Steinberg","year":"2010","unstructured":"Steinberg MH, McCarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, Ataga K, Swerdlow P, Kutlar A, DeCastro L, Waclawiw MA (2010) The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol 85(6):403\u2013408. https:\/\/doi.org\/10.1002\/ajh.21699","journal-title":"Am J Hematol"},{"issue":"4","key":"6216_CR30","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/00043426-199707000-00009","volume":"19","author":"M de Montalembert","year":"1997","unstructured":"de Montalembert M, Belloy M, Bernaudin F, Gouraud F, Capdeville R, Mardini R, Philippe N, Jais JP, Bardakdjian J, Ducrocq R, Maier-Redelsperger M, Elion J, Labie D, Girot R (1997) Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease. J Pediatr Hematol Oncol 19(4):313\u2013318. https:\/\/doi.org\/10.1097\/00043426-199707000-00009","journal-title":"J Pediatr Hematol Oncol"},{"issue":"4","key":"6216_CR31","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S0022-3476(96)70121-X","volume":"129","author":"S Jayabose","year":"1996","unstructured":"Jayabose S, Tugal O, Sandoval C, Patel P, Puder D, Lin T, Visintainer P (1996) Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J Pediatr 129(4):559\u2013565. https:\/\/doi.org\/10.1016\/S0022-3476(96)70121-X","journal-title":"J Pediatr"},{"issue":"5","key":"6216_CR32","first-page":"1550","volume":"94","author":"TR Kinney","year":"1999","unstructured":"Kinney TR, Helms RW, O\u2019Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE (1999) Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I\/II trial. Pediatr Hydroxyurea Group Blood 94(5):1550\u20131554","journal-title":"Pediatr Hydroxyurea Group Blood"},{"issue":"6","key":"6216_CR33","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1067\/mpd.2001.119590","volume":"139","author":"WC Wang","year":"2001","unstructured":"Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE (2001) A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr 139(6):790\u2013796. https:\/\/doi.org\/10.1067\/mpd.2001.119590","journal-title":"J Pediatr"},{"issue":"9778","key":"6216_CR34","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","volume":"377","author":"WC Wang","year":"2011","unstructured":"Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW (2011) Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 377(9778):1663\u20131672. https:\/\/doi.org\/10.1016\/S0140-6736(11)60355-3","journal-title":"Lancet"},{"issue":"6","key":"6216_CR35","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1182\/blood-2003-07-2475","volume":"103","author":"SA Zimmerman","year":"2004","unstructured":"Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE (2004) Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 103(6):2039\u20132045. https:\/\/doi.org\/10.1182\/blood-2003-07-2475","journal-title":"Blood"},{"issue":"6","key":"6216_CR36","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/bjh.12323","volume":"161","author":"C Lopes de Castro Lobo","year":"2013","unstructured":"Lopes de Castro Lobo C, Pinto JFC, Nascimento EM, Moura PG, Cardoso GP, Hankins JS (2013) The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. Br J Haematol 161(6):852\u2013860. https:\/\/doi.org\/10.1111\/bjh.12323","journal-title":"Br J Haematol"},{"issue":"7","key":"6216_CR37","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1182\/blood-2004-12-4973","volume":"106","author":"JS Hankins","year":"2005","unstructured":"Hankins JS, Ware RE, Rogers ZR, Wynn LW, Lane PA, Scott JP, Wang WC (2005) Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood 106(7):2269\u20132275. https:\/\/doi.org\/10.1182\/blood-2004-12-4973","journal-title":"Blood"},{"issue":"3","key":"6216_CR38","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jpeds.2004.04.058","volume":"145","author":"RE Ware","year":"2004","unstructured":"Ware RE, Zimmerman SA, Sylvestre PB, Mortier NA, Davis JS, Treem WR, Schultz WH (2004) Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr 145(3):346\u2013352. https:\/\/doi.org\/10.1016\/j.jpeds.2004.04.058","journal-title":"J Pediatr"},{"issue":"17","key":"6216_CR39","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1182\/blood-2011-11-392340","volume":"119","author":"RE Ware","year":"2012","unstructured":"Ware RE, Helms RW, for the SI (2012) Stroke with transfusions changing to Hydroxyurea (SWiTCH). Blood 119(17):3925\u20133932. https:\/\/doi.org\/10.1182\/blood-2011-11-392340","journal-title":"Blood"},{"key":"6216_CR40","doi-asserted-by":"crossref","unstructured":"Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J,Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NLC, Cohen AR, Pressel S, Adams RJ (2016) Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia\u2014TCD With Transfusions Changing to Hydroxyurea (TWiTCH):a multicentre, open-label, phase 3, non-inferiority trial. The Lancet 387 (10019):661\u2013670.doi:10.1016\/S0140-6736(15)01041-7","DOI":"10.1016\/S0140-6736(15)01041-7"},{"issue":"2","key":"6216_CR41","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1813598","volume":"380","author":"L Tshilolo","year":"2019","unstructured":"Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A, Aygun B, Stuber SE, Latham TS, McGann PT, Ware RE (2019) Hydroxyurea for children with Sickle Cell Anemia in Sub-saharan Africa. N Engl J Med 380(2):121\u2013131. https:\/\/doi.org\/10.1056\/NEJMoa1813598","journal-title":"N Engl J Med"},{"issue":"24","key":"6216_CR42","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1182\/blood-2017-06-788935","volume":"130","author":"RO Opoka","year":"2017","unstructured":"Opoka RO, Ndugwa CM, Latham TS, Lane A, Hume HA, Kasirye P, Hodges JS, Ware RE, John CC (2017) Novel use of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood 130(24):2585\u20132593. https:\/\/doi.org\/10.1182\/blood-2017-06-788935","journal-title":"Blood"},{"issue":"21","key":"6216_CR43","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1182\/blood-2017-03-771857","volume":"130","author":"I Berthaut","year":"2017","unstructured":"Berthaut I, Bachir D, Kotti S, Chalas C, Stankovic K, Eustache F, Ravel C, Habibi A, Brailly-Tabard S, L\u00e9vy-Dutel L, Bleibtreu A, Simon T, Galact\u00e9ros F, Lionnet F, Mandelbaum J (2017) Adverse effect of hydroxyurea on spermatogenesis in patients with sickle cell anemia after 6 months of treatment. Blood 130(21):2354\u20132356. https:\/\/doi.org\/10.1182\/blood-2017-03-771857","journal-title":"Blood"},{"issue":"6","key":"6216_CR44","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1182\/blood.2020008803","volume":"137","author":"DC Rees","year":"2021","unstructured":"Rees DC (2021) Hydroxyurea: coming to conclusions on safety. Blood 137(6):728\u2013729. https:\/\/doi.org\/10.1182\/blood.2020008803","journal-title":"Blood"},{"issue":"2","key":"6216_CR45","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1177\/1535370219900637","volume":"245","author":"A Sadaf","year":"2020","unstructured":"Sadaf A, Quinn CT (2020) L-glutamine for sickle cell disease: Knight or pawn? Exp Biol Med (Maywood) 245(2):146\u2013154. https:\/\/doi.org\/10.1177\/1535370219900637","journal-title":"Exp Biol Med (Maywood)"},{"issue":"8","key":"6216_CR46","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s00277-022-04867-y","volume":"101","author":"F Jafri","year":"2022","unstructured":"Jafri F, Seong G, Jang T, Cimpeanu E, Poplawska M, Dutta D, Lim SH (2022) L-glutamine for sickle cell disease: more than reducing redox. Ann Hematol 101(8):1645\u20131654. https:\/\/doi.org\/10.1007\/s00277-022-04867-y","journal-title":"Ann Hematol"},{"issue":"3","key":"6216_CR47","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1056\/NEJMoa1715971","volume":"379","author":"Y Niihara","year":"2018","unstructured":"Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP (2018) A phase 3 trial of l-Glutamine in Sickle Cell Disease. N Engl J Med 379(3):226\u2013235. https:\/\/doi.org\/10.1056\/NEJMoa1715971","journal-title":"N Engl J Med"},{"key":"6216_CR48","doi-asserted-by":"publisher","first-page":"849","DOI":"10.2147\/jpr.S278285","volume":"14","author":"NR Karki","year":"2021","unstructured":"Karki NR, Kutlar A (2021) P-Selectin blockade in the treatment of painful vaso-occlusive crises in Sickle Cell Disease: a spotlight on Crizanlizumab. J Pain Res 14:849\u2013856. https:\/\/doi.org\/10.2147\/jpr.S278285","journal-title":"J Pain Res"},{"issue":"24","key":"6216_CR49","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1182\/blood-2013-05-498311","volume":"122","author":"D Manwani","year":"2013","unstructured":"Manwani D, Frenette PS (2013) Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood 122(24):3892\u20133898. https:\/\/doi.org\/10.1182\/blood-2013-05-498311","journal-title":"Blood"},{"issue":"4","key":"6216_CR50","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/87551225211008460","volume":"37","author":"DL Stevens","year":"2021","unstructured":"Stevens DL, Hix M, Gildon BL (2021) Crizanlizumab for the Prevention of Vaso-Occlusive Pain crises in Sickle Cell Disease. J Pharm Technol 37(4):209\u2013215. https:\/\/doi.org\/10.1177\/87551225211008460","journal-title":"J Pharm Technol"},{"issue":"5","key":"6216_CR51","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJMoa1611770","volume":"376","author":"KI Ataga","year":"2017","unstructured":"Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW, Rother RP (2017) Crizanlizumab for the Prevention of Pain crises in Sickle Cell Disease. N Engl J Med 376(5):429\u2013439. https:\/\/doi.org\/10.1056\/NEJMoa1611770","journal-title":"N Engl J Med"},{"issue":"6","key":"6216_CR52","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/phar.2409","volume":"40","author":"J Han","year":"2020","unstructured":"Han J, Saraf SL, Gordeuk VR (2020) Systematic review of Crizanlizumab: a New Parenteral option to reduce Vaso-occlusive Pain crises in patients with Sickle Cell Disease. Pharmacotherapy 40(6):535\u2013543. https:\/\/doi.org\/10.1002\/phar.2409","journal-title":"Pharmacotherapy"},{"issue":"1","key":"6216_CR53","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/ajh.25308","volume":"94","author":"A Kutlar","year":"2019","unstructured":"Kutlar A, Kanter J, Liles DK, Alvarez OA, Can\u00e7ado RD, Friedrisch JR, Knight-Madden JM, Bruederle A, Shi M, Zhu Z, Ataga KI (2019) Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: a SUSTAIN study analysis. Am J Hematol 94(1):55\u201361. https:\/\/doi.org\/10.1002\/ajh.25308","journal-title":"Am J Hematol"},{"key":"6216_CR54","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1182\/blood-2018-99-111332","volume":"132","author":"N Shah","year":"2018","unstructured":"Shah N, Boccia R, Kraft WK, Hardesty BM, Paulose J, Laine D, Purkayastha D, Nandal S, Kutlar A (2018) A Multicenter Retrospective Noninterventional follow-up study in patients with Sickle Cell Pain Crisis who previously participated in the Sustain Trial in the United States Successor Study. Blood 132:4910. https:\/\/doi.org\/10.1182\/blood-2018-99-111332","journal-title":"Blood"},{"issue":"Supplement 1","key":"6216_CR55","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1182\/blood-2023-185429","volume":"142","author":"MR Abboud","year":"2023","unstructured":"Abboud MR, Can\u00e7ado RD, De Montalembert M, Smith WR, Rimawi H, Voskaridou E, Guvenc B, Keefe D, Grosch K, Nassin ML, Watson J, Yssel J, Reshetnyak E, Adomakoh YD (2023) Efficacy, Safety, and Biomarker Analysis of 5 mg and 7.5 mg doses of Crizanlizumab in patients with Sickle Cell Disease: primary analyses from the phase III STAND study. Blood 142(Supplement 1):272\u2013272. https:\/\/doi.org\/10.1182\/blood-2023-185429","journal-title":"Blood"},{"issue":"Supplement 1","key":"6216_CR56","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1182\/blood-2021-144730","volume":"138","author":"MM Heeney","year":"2021","unstructured":"Heeney MM, Rees DC, De Montalembert M, Odame I, Brown RCC, Wali Y, Nguyen TT, Lam D, Pfender N, Kanter J (2021) Initial safety and efficacy results from the phase II, Multicenter, open-label Solace-Kids Trial of Crizanlizumab in adolescents with Sickle Cell Disease (SCD). Blood 138(Supplement 1):12\u201312. https:\/\/doi.org\/10.1182\/blood-2021-144730","journal-title":"Blood"},{"issue":"Supplement 1","key":"6216_CR57","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1182\/blood-2021-149849","volume":"138","author":"SL Saraf","year":"2021","unstructured":"Saraf SL, Ataga KI, Derebail VK, Sharpe CC, Inati A, Lebensburger JD, DeBonnett L, Zhang Y, Bartolucci P (2021) A phase II, Randomized, Multicenter, open-label study evaluating the Effect of Crizanlizumab and Standard of Care (SoC) Versus Standard of Care alone on renal function in patients with chronic kidney Disease due to Sickle Cell Nephropathy (STEADFAST). Blood 138(Supplement 1):3096\u20133096. https:\/\/doi.org\/10.1182\/blood-2021-149849","journal-title":"Blood"},{"issue":"Supplement 1","key":"6216_CR58","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1182\/blood-2022-157004","volume":"140","author":"A Anderson","year":"2022","unstructured":"Anderson A, El Rassi F, DeBaun MR, Idowu M, Kanter J, Adam S, Curtis S, Liles D, Andemariam B, McLemore ML, Nickel RS, Ramadas P, Paulose J, Laine DI, Khan M, Darbari DS, Burnett AL (2022) Interim analysis of a phase 2 trial to assess the efficacy and safety of Crizanlizumab in Sickle Cell Disease patients with Priapism (SPARTAN). Blood 140(Supplement 1):1636\u20131638. https:\/\/doi.org\/10.1182\/blood-2022-157004","journal-title":"Blood"},{"issue":"3","key":"6216_CR59","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1021\/acsmedchemlett.6b00491","volume":"8","author":"B Metcalf","year":"2017","unstructured":"Metcalf B, Chuang C, Dufu K, Patel MP, Silva-Garcia A, Johnson C, Lu Q, Partridge JR, Patskovska L, Patskovsky Y, Almo SC, Jacobson MP, Hua L, Xu Q, Gwaltney SL 2nd, Yee C, Harris J, Morgan BP, James J, Xu D, Hutchaleelaha A, Paulvannan K, Oksenberg D, Li Z (2017) Discovery of GBT440, an orally bioavailable R-State stabilizer of Sickle Cell Hemoglobin. ACS Med Chem Lett 8(3):321\u2013326. https:\/\/doi.org\/10.1021\/acsmedchemlett.6b00491","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"6216_CR60","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/bjh.14214","volume":"175","author":"D Oksenberg","year":"2016","unstructured":"Oksenberg D, Dufu K, Patel MP, Chuang C, Li Z, Xu Q, Silva-Garcia A, Zhou C, Hutchaleelaha A, Patskovska L, Patskovsky Y, Almo SC, Sinha U, Metcalf BW, Archer DR (2016) GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. Br J Haematol 175(1):141\u2013153. https:\/\/doi.org\/10.1111\/bjh.14214","journal-title":"Br J Haematol"},{"issue":"17","key":"6216_CR61","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1182\/blood-2018-08-868893","volume":"133","author":"J Howard","year":"2019","unstructured":"Howard J, Hemmaway CJ, Telfer P, Layton DM, Porter J, Awogbade M, Mant T, Gretler DD, Dufu K, Hutchaleelaha A, Patel M, Siu V, Dixon S, Landsman N, Tonda M, Lehrer-Graiwer J (2019) A phase 1\/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease. Blood 133(17):1865\u20131875. https:\/\/doi.org\/10.1182\/blood-2018-08-868893","journal-title":"Blood"},{"issue":"6","key":"6216_CR62","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/bcp.13896","volume":"85","author":"A Hutchaleelaha","year":"2019","unstructured":"Hutchaleelaha A, Patel M, Washington C, Siu V, Allen E, Oksenberg D, Gretler DD, Mant T, Lehrer-Graiwer J (2019) Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease. Br J Clin Pharmacol 85(6):1290\u20131302. https:\/\/doi.org\/10.1111\/bcp.13896","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"6216_CR63","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa1903212","volume":"381","author":"E Vichinsky","year":"2019","unstructured":"Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC, Diuguid DL, Telfer P, Tsitsikas DA, Elghandour A, Gordeuk VR, Kanter J, Abboud MR, Lehrer-Graiwer J, Tonda M, Intondi A, Tong B, Howard J (2019) A phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. N Engl J Med 381(6):509\u2013519. https:\/\/doi.org\/10.1056\/NEJMoa1903212","journal-title":"N Engl J Med"},{"issue":"5","key":"6216_CR64","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1016\/S2352-3026(21)00059-4","volume":"8","author":"J Howard","year":"2021","unstructured":"Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E (2021) Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol 8(5):e323\u2013e333. https:\/\/doi.org\/10.1016\/S2352-3026(21)00059-4","journal-title":"Lancet Haematol"},{"issue":"8","key":"6216_CR65","doi-asserted-by":"publisher","first-page":"e29716","DOI":"10.1002\/pbc.29716","volume":"69","author":"JH Estepp","year":"2022","unstructured":"Estepp JH, Kalpatthi R, Woods G, Trompeter S, Liem RI, Sims K, Inati A, Inusa BPD, Campbell A, Piccone C, Abboud MR, Smith-Whitley K, Dixon S, Tonda M, Washington C, Griffin NM, Brown C (2022) Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years. Pediatr Blood Cancer 69(8):e29716. https:\/\/doi.org\/10.1002\/pbc.29716","journal-title":"Pediatr Blood Cancer"},{"key":"6216_CR66","doi-asserted-by":"crossref","unstructured":"Minniti CP, Billett HH, McMahon D, Idowu M, Shah N, Drachtman RA, Sharma A, Glaros A, Achebe MOO, Nero AC, Curtis S, Andemariam B (2022) Leg Ulcer Prevalence and Outcomes in a Real-World, Multicenter, Retrospective Study of Patients Treated with Voxelotor. In: ASH Annual Meeting, New Orleans, Louisiana, USA","DOI":"10.1182\/blood-2022-169334"},{"issue":"Supplement 1","key":"6216_CR67","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2020-140539","volume":"136","author":"K Dufu","year":"2020","unstructured":"Dufu K, Alt C, Strutt S, Tang T, Liao-Zou H, Yuan Y, Cathers BE, Oksenberg D (2020) GBT021601 inhibits HbS polymerization, prevents RBC Sickling and improves the pathophysiology of Sickle Cell Disease in a murine model. Blood 136(Supplement 1):7\u20138. https:\/\/doi.org\/10.1182\/blood-2020-140539","journal-title":"Blood"},{"key":"6216_CR68","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1182\/blood-2021-152924","volume":"138","author":"RCC Brown","year":"2021","unstructured":"Brown RCC, Redfern A, Lisbon E, Washington C, Agodoa I, Smith-Whitley K (2021) GBT021601, a next generation HbS polymerization inhibitor: results of safety, tolerability, pharmacokinetics and pharmacodynamics in adults living with Sickle Cell Disease and healthy volunteers. Blood 138:3099. https:\/\/doi.org\/10.1182\/blood-2021-152924","journal-title":"Blood"},{"key":"6216_CR69","doi-asserted-by":"crossref","unstructured":"Brown C, Key C, Agodoa I, Olbertz J, Duchin K, Barth A, Lisbon esafety, tolerability, and pharmacokinetic\/pharmacodynamic results from phase 1 studies of gbt021601, a next-generation hbs polymerization inhibitor for treatment of sickle cell diseasE (2022). In: EHA2022, Vienna, Austria","DOI":"10.1097\/01.HS9.0000843964.45576.92"},{"key":"6216_CR70","doi-asserted-by":"crossref","unstructured":"Idowu M, Nguyen T, Lewis D, Lipato T, Buckley EM, Brothers R, Akbar M, Triplett S, Dufu K, Lisbon E (2022) Pharmacodynamic Results from Phase 1 Studies of GBT021601, a Next-Generation HbS Polymerization Inhibitor for Treatment of Sickle Cell Disease. In: ASH Annual Meeting, New Orleans, Louisiana, USA","DOI":"10.1182\/blood-2022-167997"},{"key":"6216_CR71","unstructured":"Global Blood T (2026) GBT021601-021: A Study in Adult and Pediatric Participants With SCD"},{"issue":"9","key":"6216_CR72","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1182\/bloodadvances.2020003604","volume":"5","author":"A Shrestha","year":"2021","unstructured":"Shrestha A, Chi M, Wagner K, Malik A, Korpik J, Drake A, Fulzele K, Guichard S, Malik P (2021) FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and hb levels in SCA mice. Blood Adv 5(9):2385\u20132390. https:\/\/doi.org\/10.1182\/bloodadvances.2020003604","journal-title":"Blood Adv"},{"key":"6216_CR73","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood-2020-134269","volume":"136","author":"R Brown","year":"2020","unstructured":"Brown R, Cruz K, Kalfa T, Kuypers F, Saraf S, Estepp J, Smart L, Malik P, Lerman M, Mayer R, Ribadeneira M, Forsyth S, Schroeder P, Wu E, Kelly P, Telen M (2020) FT-4202, an Allosteric activator of pyruvate Kinase-R, demonstrates proof of mechanism and proof of Concept after a single dose and after multiple daily doses in a phase 1 study of patients with Sickle Cell Disease. Blood 136:19\u201320. https:\/\/doi.org\/10.1182\/blood-2020-134269","journal-title":"Blood"},{"issue":"Supplement 1","key":"6216_CR74","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1182\/blood-2024-204962","volume":"144","author":"S Delicou","year":"2024","unstructured":"Delicou S, El Rassi F, Andemariam B, Abboud MR, Kanter J, Telen MJ, Githanga J, Inati A, Idris I, Navani S, Wu E, Eisenberger A (2024) Etavopivat reduces incidence of Vaso-occlusive crises in patients with Sickle Cell Disease: HIBISCUS Trial Phase 2 results through 52 weeks. Blood 144(Supplement 1):179\u2013179. https:\/\/doi.org\/10.1182\/blood-2024-204962","journal-title":"Blood"},{"issue":"24","key":"6216_CR75","doi-asserted-by":"publisher","first-page":"7539","DOI":"10.1182\/bloodadvances.2023011477","volume":"7","author":"MJ van Dijk","year":"2023","unstructured":"van Dijk MJ, Rab MAE, van Oirschot BA, Bos J, Derichs C, Rijneveld AW, Cnossen MH, Nur E, Biemond BJ, Bartels M, Jans JJM, van Solinge WW, Schutgens REG, van Wijk R, van Beers EJ (2023) One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study. Blood Adv 7(24):7539\u20137550. https:\/\/doi.org\/10.1182\/bloodadvances.2023011477","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"6216_CR76","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1182\/blood-2023-187033","volume":"142","author":"M Idowu","year":"2023","unstructured":"Idowu M, Otieno L, Dumitriu B, Lobo CL, Thein SL, Andemariam B, Nnodu OE, Inati A, Glaros AK, Saad STO, Bartolucci P, Colombatti R, Taher AT, Abboud MR, Oluyadi A, Iyer V, Yin O, Morris S, Yates AM, Shao H, Patil S, Urbstonaitis R, Zaidi AU, Smith WR (2023) A phase 2\/3, Double-Blind, randomized, Placebo-Controlled, Multicenter Study of Mitapivat in patients with Sickle Cell Disease: RISE UP phase 2 results. Blood 142(Supplement 1):271\u2013271. https:\/\/doi.org\/10.1182\/blood-2023-187033","journal-title":"Blood"},{"key":"6216_CR77","doi-asserted-by":"crossref","unstructured":"Dai Y, Hill K, Harris D, Shen T, Yuan C-X, Gasteyger CA (2022) Phase 2a, Randomized, Open-Label Study to Evaluate Multiple Dosing Regimens of Subcutaneous ALXN1820 in Adult Patients with Sickle Cell Disease. In: ASH Annual Meeting, New Orleans, Louisiana, USA","DOI":"10.1182\/blood-2022-166694"},{"key":"6216_CR78","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2147\/jbm.S287301","volume":"12","author":"C Varelas","year":"2021","unstructured":"Varelas C, Tampaki A, Sakellari I, Anagnostopoulos \u0391, Gavriilaki E, Vlachaki E (2021) Complement in Sickle Cell Disease: are we ready for Prime Time? J Blood Med 12:177\u2013187. https:\/\/doi.org\/10.2147\/jbm.S287301","journal-title":"J Blood Med"},{"issue":"5","key":"6216_CR79","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/ajh.25742","volume":"95","author":"LT Roumenina","year":"2020","unstructured":"Roumenina LT, Chadebech P, Bodivit G, Vieira-Martins P, Grunenwald A, Boudhabhay I, Poillerat V, Pakdaman S, Kiger L, Jouard A, Audureau E, Pirenne F, Galact\u00e9ros F, Fr\u00e9meaux-Bacchi V, Bartolucci P (2020) Complement activation in sickle cell disease: dependence on cell density, hemolysis and modulation by hydroxyurea therapy. Am J Hematol 95(5):456\u2013464. https:\/\/doi.org\/10.1002\/ajh.25742","journal-title":"Am J Hematol"},{"issue":"5","key":"6216_CR80","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/ajh.25742","volume":"95","author":"LT Roumenina","year":"2020","unstructured":"Roumenina LT, Chadebech P, Bodivit G, Vieira-Martins P, Grunenwald A, Boudhabhay I, Poillerat V, Pakdaman S, Kiger L, Jouard A, Audureau E, Pirenne F, Galact\u00e9ros F, Fr\u00e9meaux-Bacchi V, Bartolucci P (2020) Complement activation in sickle cell disease: dependence on cell density, hemolysis and modulation by hydroxyurea therapy. Am J Hematol 95(5):456\u2013464. https:\/\/doi.org\/10.1002\/ajh.25742","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"6216_CR81","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1182\/blood-2021-147854","volume":"138","author":"P Bartolucci","year":"2021","unstructured":"Bartolucci P, Ataga KI, Callaghan MU, De Franceschi L, Minniti C, Alexandrou A, Imbs D-C, Fox R, Patel H, Sostelly A, Schimmel J (2021) Trial in Progress: the Randomized, Double-Blind, placebo-controlled phase ib CROSSWALK-a Trial evaluating the safety of Crovalimab for the management of Acute Uncomplicated Vaso-Occlusive episodes (VOEs) in patients with sickle cell disease (SCD). Blood 138(Supplement 1):3108\u20133108. https:\/\/doi.org\/10.1182\/blood-2021-147854","journal-title":"Blood"},{"issue":"4","key":"6216_CR82","doi-asserted-by":"publisher","first-page":"L314","DOI":"10.1152\/ajplung.00252.2014","volume":"308","author":"KP Potoka","year":"2015","unstructured":"Potoka KP, Gladwin MT (2015) Vasculopathy and pulmonary hypertension in sickle cell disease. Am J Physiol Lung Cell Mol Physiol 308(4):L314\u2013324. https:\/\/doi.org\/10.1152\/ajplung.00252.2014","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"4","key":"6216_CR83","doi-asserted-by":"publisher","first-page":"204589401879180","DOI":"10.1177\/2045894018791802","volume":"8","author":"NA Weir","year":"2018","unstructured":"Weir NA, Conrey A, Lewis D, Mehari A (2018) Riociguat use in sickle cell related chronic thromboembolic pulmonary hypertension: a case series. Pulm Circ 8(4):2045894018791802. https:\/\/doi.org\/10.1177\/2045894018791802","journal-title":"Pulm Circ"},{"key":"6216_CR84","doi-asserted-by":"publisher","unstructured":"Pilo F, Angelucci E (2024) Vamifeport: Monography of the first oral ferroportin inhibitor. J Clin Med 13(18). https:\/\/doi.org\/10.3390\/jcm13185524","DOI":"10.3390\/jcm13185524"},{"issue":"7","key":"6216_CR85","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1182\/blood.2021014716","volume":"140","author":"N Nyffenegger","year":"2022","unstructured":"Nyffenegger N, Zennadi R, Kalleda N, Flace A, Ingoglia G, Buzzi RM, Doucerain C, Buehler PW, Schaer DJ, D\u00fcrrenberger F, Manolova V (2022) The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease. Blood 140(7):769\u2013781. https:\/\/doi.org\/10.1182\/blood.2021014716","journal-title":"Blood"},{"key":"6216_CR86","doi-asserted-by":"publisher","unstructured":"Gentinetta T, Belcher JD, Br\u00fcgger-Verdon V, Adam J, Ruthsatz T, Bain J, Schu D, Ventrici L, Edler M, Lioe H, Patel K, Chen C, Nguyen J, Abdulla F, Zhang P, Wassmer A, Jain M, Mischnik M, Pelzing M, Martin K, Davis R, Didichenko S, Schaub A, Brinkman N, Herzog E, Z\u00fcrcher A, Vercellotti GM, Kato GJ, H\u00f6barth G (2022) Plasma-Derived Hemopexin as a candidate Therapeutic Agent for Acute Vaso-occlusion in Sickle Cell Disease: preclinical evidence. J Clin Med 11(3). https:\/\/doi.org\/10.3390\/jcm11030630","DOI":"10.3390\/jcm11030630"},{"key":"6216_CR87","doi-asserted-by":"publisher","unstructured":"Shore PM, Biemond BJ, Kesse-Adu R, Wahab E, Desai PC, Boucher A, Eleftheriou P, Rijneveld A, De Castro LM, Bergmann S, Kato GJ, Jochems J, Wilson F, Jung K, Gordeuk VR (2024) Phase 1 study of the Safety and Pharmacokinetics of CSL889 (Hemopexin) in adults with SCD. J Sickle Cell Disease 1(Supplement1). https:\/\/doi.org\/10.1093\/jscdis\/yoae002.003","DOI":"10.1093\/jscdis\/yoae002.003"},{"issue":"24","key":"6216_CR88","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.1182\/bloodadvances.2020003519","volume":"4","author":"S Allali","year":"2020","unstructured":"Allali S, de Montalembert M, Rignault-Bricard R, Taylor M, Brice J, Brousse V, Talbot J-M, Moulin F, Heilbronner C, Hermine O, Maciel TT (2020) IL-6 levels are dramatically high in the sputum from children with sickle cell disease during acute chest syndrome. Blood Adv 4(24):6130\u20136134. https:\/\/doi.org\/10.1182\/bloodadvances.2020003519","journal-title":"Blood Adv"},{"issue":"4","key":"6216_CR89","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/jha2.779","volume":"4","author":"N Desai","year":"2023","unstructured":"Desai N, Peters J, Davies E, Sharif J (2023) The role of tocilizumab in the treatment of post-transfusion hyperhaemolysis. EJHaem 4(4):1096\u20131099. https:\/\/doi.org\/10.1002\/jha2.779","journal-title":"EJHaem"},{"issue":"11","key":"6216_CR90","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.3324\/haematol.2021.280233","volume":"107","author":"P Rossato","year":"2022","unstructured":"Rossato P, Federti E, Matte A, Glantschnig H, Canneva F, Schuster M, Coulibaly S, Schrenk G, Voelkel D, Dockal M, Plaimauer B, Andolfo I, Iolascon A, Rottensteiner H, Gritsch H, Scheiflinger F, Hoellriegl W, Franceschi L (2022) Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease. Haematologica 107(11):2650\u20132660. https:\/\/doi.org\/10.3324\/haematol.2021.280233","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"6216_CR91","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1182\/blood-2021-146150","volume":"138","author":"P Patwari","year":"2021","unstructured":"Patwari P, Nguyen VA, Bhattacharya I, Jain N (2021) Recombinant ADAMTS13 for patients with Sickle Cell Disease: design of a phase 1 safety, tolerability, Pharmacokinetics, and Pharmacodynamics Study. Blood 138(Supplement 1):3118\u20133118. https:\/\/doi.org\/10.1182\/blood-2021-146150","journal-title":"Blood"},{"issue":"6","key":"6216_CR92","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/fjc.0000000000000233","volume":"65","author":"C Schmitt","year":"2015","unstructured":"Schmitt C, Abt M, Ciorciaro C, Kling D, Jamois C, Schick E, Solier C, Benghozi R, Gaudreault J (2015) First-in-Man Study with Inclacumab, a human monoclonal antibody against P-selectin. J Cardiovasc Pharmacol 65(6):611\u2013619. https:\/\/doi.org\/10.1097\/fjc.0000000000000233","journal-title":"J Cardiovasc Pharmacol"},{"issue":"9","key":"6216_CR93","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00228-023-03514-3","volume":"79","author":"CL Mayer","year":"2023","unstructured":"Mayer CL, Koeck K, Hottmann M, Redfern A, Davis M, Barth A, Geng X, Hoppe C, Yue P (2023) A phase 1 study in healthy participants to characterize the safety and pharmacology of inclacumab, a fully human anti-P-selectin antibody, in development for treatment of sickle cell disease. Eur J Clin Pharmacol 79(9):1219\u20131228. https:\/\/doi.org\/10.1007\/s00228-023-03514-3","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"6216_CR94","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1182\/blood.2022015797","volume":"141","author":"CD Dampier","year":"2023","unstructured":"Dampier CD, Telen MJ, Wun T, Brown RC, Desai P, El Rassi F, Fuh B, Kanter J, Pastore Y, Rothman J, Taylor JG, Readett VI, Sivamurthy D, Tammara KM, Tseng B, Lozier L-J, Thackray JN, Magnani H, Hassell JL, Investigators obotR (2023) A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis. Blood 141(2):168\u2013179. https:\/\/doi.org\/10.1182\/blood.2022015797","journal-title":"Blood"},{"issue":"5","key":"6216_CR95","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/s2352-3026(21)00053-3","volume":"8","author":"BJ Biemond","year":"2021","unstructured":"Biemond BJ, Tombak A, Kilinc Y, Al-Khabori M, Abboud M, Nafea M, Inati A, Wali Y, Kristensen J, Kowalski J, Donnelly E, Ohd J (2021) Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol 8(5):e334\u2013e343. https:\/\/doi.org\/10.1016\/s2352-3026(21)00053-3","journal-title":"Lancet Haematol"},{"key":"6216_CR96","doi-asserted-by":"publisher","first-page":"102482","DOI":"10.1016\/j.ctim.2020.102482","volume":"52","author":"AA Daak","year":"2020","unstructured":"Daak AA, Lopez-Toledano MA, Heeney MM (2020) Biochemical and therapeutic effects of Omega-3 fatty acids in sickle cell disease. Complement Ther Med 52:102482. https:\/\/doi.org\/10.1016\/j.ctim.2020.102482","journal-title":"Complement Ther Med"},{"issue":"2","key":"6216_CR97","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.bcmd.2014.11.004","volume":"54","author":"NJ Wandersee","year":"2015","unstructured":"Wandersee NJ, Maciaszek JL, Giger KM, Hanson MS, Zheng S, Guo Y, Mickelson B, Hillery CA, Lykotrafitis G, Low PS (2015) Dietary supplementation with docosahexanoic acid (DHA) increases red blood cell membrane flexibility in mice with sickle cell disease. Blood Cells Molecules Dis 54(2):183\u2013188","journal-title":"Blood Cells Molecules Dis"},{"issue":"7","key":"6216_CR98","doi-asserted-by":"publisher","first-page":"870","DOI":"10.3324\/haematol.2015.124586","volume":"100","author":"BT Kalish","year":"2015","unstructured":"Kalish BT, Matte A, Andolfo I, Iolascon A, Weinberg O, Ghigo A, Cimino J, Siciliano A, Hirsch E, Federti E (2015) Dietary \u03c9-3 fatty acids protect against vasculopathy in a transgenic mouse model of sickle cell disease. Haematologica 100(7):870","journal-title":"Haematologica"},{"key":"6216_CR99","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-pathmechdis-012418-012838","volume":"14","author":"P Sundd","year":"2019","unstructured":"Sundd P, Gladwin MT, Novelli EM (2019) Pathophysiology of Sickle Cell Disease. Annu Rev Pathol 14:263\u2013292. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-012418-012838","journal-title":"Annu Rev Pathol"},{"issue":"11","key":"6216_CR100","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.3324\/haematol.2017.169581","volume":"102","author":"SD Arnold","year":"2017","unstructured":"Arnold SD, Brazauskas R, He N, Li Y, Aplenc R, Jin Z, Hall M, Atsuta Y, Dalal J, Hahn T, Khera N, Bonfim C, Majhail NS, Diaz MA, Freytes CO, Wood WA, Savani BN, Kamble RT, Parsons S, Ahmed I, Sullivan K, Beattie S, Dandoy C, Munker R, Marino S, Bitan M, Abdel-Azim H, Aljurf M, Olsson RF, Joshi S, Buchbinder D, Eckrich MJ, Hashmi S, Lazarus H, Marks DI, Steinberg A, Saad A, Gergis U, Krishnamurti L, Abraham A, Rangarajan HG, Walters M, Lipscomb J, Saber W, Satwani P (2017) Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. Haematologica 102(11):1823\u20131832. https:\/\/doi.org\/10.3324\/haematol.2017.169581","journal-title":"Haematologica"},{"issue":"7","key":"6216_CR101","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.3324\/haematol.2020.270546","volume":"106","author":"GE Linder","year":"2021","unstructured":"Linder GE, Chou ST (2021) Red cell transfusion and alloimmunization in sickle cell disease. Haematologica 106(7):1805\u20131815. https:\/\/doi.org\/10.3324\/haematol.2020.270546","journal-title":"Haematologica"},{"issue":"17","key":"6216_CR102","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1182\/blood.2021013674","volume":"139","author":"DC Rees","year":"2022","unstructured":"Rees DC, Kilinc Y, Unal S, Dampier C, Pace BS, Kaya B, Trompeter S, Odame I, Mahlangu J, Unal S, Brent J, Grosse R, Fuh BR, Inusa BPD, Koren A, Leblebisatan G, Levin C, McNamara E, Meiser K, Hom D, Oliver SJ (2022) A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia. Blood 139(17):2642\u20132652. https:\/\/doi.org\/10.1182\/blood.2021013674","journal-title":"Blood"},{"issue":"4","key":"6216_CR103","doi-asserted-by":"publisher","first-page":"e452","DOI":"10.1097\/hs9.0000000000000452","volume":"4","author":"I Hegemann","year":"2020","unstructured":"Hegemann I, Sasselli C, Valeri F, Makhro A, M\u00fcller R, Bogdanova A, Manz MG, Gassmann M, Goede JS (2020) MEMSID: results from a phase 2 pilot study on Memantine Treatment for Sickle Cell Disease. Hemasphere 4(4):e452. https:\/\/doi.org\/10.1097\/hs9.0000000000000452","journal-title":"Hemasphere"},{"issue":"13","key":"6216_CR104","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1182\/blood.2021014095","volume":"140","author":"MM Heeney","year":"2022","unstructured":"Heeney MM, Abboud MR, Githanga J, Inusa BPD, Kanter J, Michelson AD, Nduba V, Musiime V, Apte M, Inati A, Taksande AM, Andersson M, \u00c5strand M, Maklad N, Niazi M, Himmelmann A, Berggren AR, investigators obotHs (2022) Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study. Blood 140(13):1470\u20131481. https:\/\/doi.org\/10.1182\/blood.2021014095","journal-title":"Blood"},{"issue":"2","key":"6216_CR105","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1517\/13543780802708011","volume":"18","author":"KI Ataga","year":"2009","unstructured":"Ataga KI, Stocker J (2009) Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia. Expert Opin Investig Drugs 18(2):231\u2013239. https:\/\/doi.org\/10.1517\/13543780802708011","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"6216_CR106","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1365-2141.2010.08520.x","volume":"153","author":"KI Ataga","year":"2011","unstructured":"Ataga KI, Reid M, Ballas SK, Yasin Z, Bigelow C, James LS, Smith WR, Galacteros F, Kutlar A, Hull JH, Stocker JW (2011) Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). Br J Haematol 153(1):92\u2013104. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08520.x","journal-title":"Br J Haematol"},{"issue":"20","key":"6216_CR107","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/nejm199505183322001","volume":"332","author":"S Charache","year":"1995","unstructured":"Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 332(20):1317\u20131322. https:\/\/doi.org\/10.1056\/nejm199505183322001","journal-title":"N Engl J Med"},{"issue":"6","key":"6216_CR108","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ajh.21699","volume":"85","author":"MH Steinberg","year":"2010","unstructured":"Steinberg MH, McCarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, Ataga K, Swerdlow P, Kutlar A, DeCastro L, Waclawiw MA (2010) The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol 85(6):403\u2013408. https:\/\/doi.org\/10.1002\/ajh.21699","journal-title":"Am J Hematol"},{"issue":"4","key":"6216_CR109","doi-asserted-by":"publisher","first-page":"Cd002202","DOI":"10.1002\/14651858.CD002202.pub2","volume":"4","author":"SJ Nevitt","year":"2017","unstructured":"Nevitt SJ, Jones AP, Howard J (2017) Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database Syst Rev 4(4):Cd002202. https:\/\/doi.org\/10.1002\/14651858.CD002202.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"6216_CR110","doi-asserted-by":"publisher","first-page":"204062072110011","DOI":"10.1177\/20406207211001136","volume":"12","author":"AK Glaros","year":"2021","unstructured":"Glaros AK, Razvi R, Shah N, Zaidi AU (2021) Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor. Ther Adv Hematol 12:20406207211001136. https:\/\/doi.org\/10.1177\/20406207211001136","journal-title":"Ther Adv Hematol"},{"issue":"2","key":"6216_CR111","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1177\/1060028020943059","volume":"55","author":"LB Herity","year":"2021","unstructured":"Herity LB, Vaughan DM, Rodriguez LR, Lowe DK (2021) Voxelotor: a Novel treatment for Sickle Cell Disease. Ann Pharmacother 55(2):240\u2013245. https:\/\/doi.org\/10.1177\/1060028020943059","journal-title":"Ann Pharmacother"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06216-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06216-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06216-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T14:36:02Z","timestamp":1743863762000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06216-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":111,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["6216"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06216-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]},"assertion":[{"value":"2 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"None of the authors have any financial or non-financial conflicts of interest with regard to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}